

Accumulation and metabolism of $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ in muscarinic-receptor-stimulated SH-SY5Y neuroblastoma cells

David G. LAMBERT,* R. A. John CHALLISS and Stefan R. NAHORSKI

Department of Pharmacology and Therapeutics, University of Leicester, P.O. Box 138, Medical Sciences Building, University Road, Leicester LE1 9HN, U.K.

Stimulation of M_3 muscarinic receptors expressed by SH-SY5Y cells induced a dose- and time-related increase in the mass of $\text{Ins}(1,4,5)P_3$ (basal 38.3 ± 5.8 pmol/mg of protein) and $\text{Ins}(1,3,4,5)P_4$ (basal 6.1 ± 1.2 pmol/mg of protein). Comparison of radioreceptor mass assays with [^3H]inositol labelling showed higher-fold stimulations with the former protocol. The later accumulation of $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ mass was dependent upon extracellular Ca^{2+} .

INTRODUCTION

Agonist occupancy of several diverse cell-surface receptors including various muscarinic subtypes leads to a guanine-nucleotide-sensitive hydrolysis of phosphoinositides and the generation of diacylglycerol and $\text{Ins}(1,4,5)P_3$. Both of these products are believed to act as second messengers, with the latter interacting with a specific receptor and releasing Ca^{2+} from non-mitochondrial intracellular sites [1–3]. There is also increasing evidence that a phosphorylation product of $\text{Ins}(1,4,5)P_3$, i.e. $\text{Ins}(1,3,4,5)P_4$, may also control Ca^{2+} homeostasis by controlling Ca^{2+} entry across the plasma membrane or Ca^{2+} movement between different intracellular stores [4].

In recent studies we have used the human neuroblastoma SK-N-SH and particularly its neuronal clone SH-SY5Y as model systems to examine these potential actions of inositol polyphosphates in Ca^{2+} homeostasis. These cells stably express a single (M_3) subclass of muscarinic receptor [5,6] that is linked to phosphoinositide metabolism and changes in intracellular Ca^{2+} [7,8]. In particular, we have recently detailed the characteristics of muscarinic-receptor-induced Ca^{2+} mobilization and entry across the plasma membrane in intact SH-SY5Y cells and have associated a dramatic early accumulation of $\text{Ins}(1,4,5)P_3$ mass with the release of the intracellular Ca^{2+} stores [9]. In the present studies we have extended these observations by assessing the mass accumulation of both $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ using highly specific receptor assays. Furthermore, by labelling these cells with [^3H]inositol and separating various isomeric species of [^3H]inositol polyphosphates, we have been able to compare labelled and mass data and make estimates of the proportion of metabolism that occurs by phosphorylation or dephosphorylation. Our observations are discussed in relation to accompanying changes in the intracellular Ca^{2+} concentration ($[\text{Ca}^{2+}]_i$) when cells are incubated in the presence or absence of extracellular Ca^{2+} .

MATERIALS AND METHODS

Cell culture

SH-SY5Y cells (passages 60–100) were cultured in minimum essential medium supplemented with 2 mM-L-glutamine, 100 units of penicillin/ml, 100 μg of streptomycin/ml, 2.5 μg of fungizone/ml and 10% (v/v) foetal calf serum as described previously [5,9].

Measurement of [^3H]inositol phosphate production

All experiments were performed with SH-SY5Y cells suspended in Krebs buffer of the following composition (mM): Na^+ (143.3), K^+ (5.9), Mg^{2+} (1.2), Ca^{2+} (1.3), Cl^- (128.3), $\text{H}_2\text{PO}_4^{2-}$ (2.2), HCO_3^- (24.9), SO_4^{2-} (1.2) and glucose (10), pH 7.4. SH-SY5Y cells were prelabelled for 24–48 h (48 h for h.p.l.c.) with 4–10 μCi of *myo*-[2- ^3H]inositol/ml (10 μCi /ml for h.p.l.c.). Suspensions of labelled cells were then stimulated (300 μl final volumes) with carbachol. All reactions were terminated with an equal volume of trichloroacetic acid (1 M). [^3H]inositol phosphates were extracted with Freon/octylamine and neutralized with bicarbonate as described previously [9]. [^3H]inositol phosphates were separated either by conventional Dowex anion-exchange chromatography [10,11] or by h.p.l.c. [12]. The latter separation was achieved with a Partisil (10 μm) SAX analytical column, and separation of isomers has been carefully validated by co-elution with authentic ^3H -labelled inositol (poly)phosphate standards in separate runs and/or by co-elution with internal ^{14}C - or ^{32}P -labelled inositol phosphate standards [12].

Measurement of $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ mass

Assays were performed using radioreceptor methods previously described and evaluated in this laboratory for stereo- and positional specificity [13,14]. Briefly, intact SH-SY5Y cells (approx. 1 mg of protein), harvested with EDTA (this reduces membrane disturbance and increases reproducibility compared with scrape-harvesting; see [9]), were preincubated for 5 min at 37 °C. Carbachol was then added for the indicated time periods. The reaction was terminated, and $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ were extracted and neutralized as described above. $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ were quantified using bovine adrenal cortical and rat cerebellar binding proteins respectively at 4 °C [13,14]. Authentic $\text{Ins}(1,4,5)P_3$ and $\text{Ins}(1,3,4,5)P_4$ (0.036–36 pmol) were prepared in buffer, taken through an identical extraction and used as standards. Appropriate treatment of standards is essential to obtain authentic tissue estimates. [^3H] $\text{Ins}(1,4,5)P_3$ and [^{32}P] $\text{Ins}(1,3,4,5)P_4$ were used as radioligands {in some assays [^3H] $\text{Ins}(1,3,4,5)P_4$ was used}. Non-specific binding was defined in the presence of excess D/L- $\text{Ins}(1,4,5)P_3$ (10 μM) for $\text{Ins}(1,4,5)P_3$ determinations and D/L- $\text{Ins}(1,3,4,5)P_4$ (10 μM) for $\text{Ins}(1,3,4,5)P_4$ determinations. Bound and free ligand were separated by rapid filtration. [^3H] $\text{Ins}(1,4,5)P_3$ (17–20 Ci/mmol), [^3H] $\text{Ins}(1,3,4,5)P_4$

Abbreviations used: $[\text{Ca}^{2+}]_i$, intracellular Ca^{2+} concn.; EC_{50} , concn. causing half-maximum stimulation.

* To whom correspondence should be addressed.




Fig. 1. Time- and dose-related accumulation of carbachol-stimulated inositol tris- and tetrakis-phosphate in SH-SY5Y human neuroblastoma cells

(a) Time-related accumulation of $[^3\text{H}]\text{InsP}_3$ (■) and $[^3\text{H}]\text{InsP}_4$ (□) in response to carbachol (1 mM). Cells were prelabelled with $4\ \mu\text{Ci}$ of *myo*- $[^3\text{H}]\text{inositol}$ /ml for 24 h. Inositol phosphates were separated by Dowex anion-exchange chromatography (see the text). Data are means \pm S.E.M. ($n = 3$). Basal radioactivity was as follows: $[^3\text{H}]\text{InsP}_3$, 204 ± 27 d.p.m.; $[^3\text{H}]\text{InsP}_4$, 270 ± 27 d.p.m. Basal radioactivity was unchanged at 300 s. * $P < 0.05$ compared with basal. (b) Dose-related accumulation of $\text{Ins}(1,4,5)\text{P}_3$ (■) and $\text{Ins}(1,3,4,5)\text{P}_4$ (□) mass. Basal $\text{Ins}(1,4,5)\text{P}_3$ mass was 24 ± 3 pmol/mg of protein, and $\text{Ins}(1,3,4,5)\text{P}_4$ mass was 4.5 ± 0.4 pmol/mg of protein. * $P < 0.05$ compared with basal. (c) and (d) Effect of removal of external Ca^{2+} (+0.1 mM-EGTA) on $\text{Ins}(1,4,5)\text{P}_3$ (c) and $\text{Ins}(1,3,4,5)\text{P}_4$ (d) mass accumulation in carbachol (1 mM)-stimulated SH-SY5Y human neuroblastoma cells. Removal of external Ca^{2+} (+0.1 mM-EGTA) did not alter the peak production of either polyphosphate. * $P < 0.05$ compared with Ca^{2+} -replete. ■, $+\text{Ca}^{2+}$; □, $-\text{Ca}^{2+}$. All data are means \pm S.E.M. ($n = 3-8$).

(17–20 Ci/mmol) and $[^{32}\text{P}]\text{Ins}(1,3,4,5)\text{P}_4$ (100 Ci/mmol) used above were generously provided by NEN (Du Pont).

Data analysis

Data are expressed as means \pm S.E.M. of at least three determinations. EC_{50} (half-maximum stimulation) values were obtained by computer-assisted curve fitting using ALLFIT [15]. Where appropriate, statistical significance was assessed by Student's *t* test and was considered to be significant when $P < 0.05$.

RESULTS AND DISCUSSION

Previous studies in both the parent SK-N-SH cell and the neuronal clone SH-SY5Y from this [5,9,16] and other laboratories [6,8] have shown that muscarinic M_3 receptor occupation by appropriate agonists leads to increased phosphoinositide metabolism, release of intracellular stored Ca^{2+} and Ca^{2+} entry across the plasma membrane. The present studies, however, provide the first detailed analysis of inositol polyphosphate isomers using both labelling and mass assays and have allowed assessment of their potential role in Ca^{2+} signalling in response to muscarinic receptor stimulation in these cells.

In initial experiments, $[^3\text{H}]\text{inositol}$ phosphates were separated by Dowex anion-exchange chromatography to describe the time course of accumulation. Addition of carbachol (1 mM) to prelabelled cells caused a time-related accumulation of InsP_3 , reaching a peak of 226% above basal some 5–10 s after agonist

addition. The pattern of InsP_3 production was biphasic, with a new apparent steady state being reached (approx. 100% above basal values) by 2 min and maintained for at least a further 3 min. $[^3\text{H}]\text{InsP}_4$ reached a peak accumulation (50%) some 30–60 s after muscarinic receptor stimulation and remained relatively constant for at least 5 min (Fig. 1a).

The time-related increases in $[^3\text{H}]\text{inositol}$ polyphosphates described above were confirmed and extended by examining two time points (10 and 300 s) using h.p.l.c. (Table 1). Significant increases (162%) in $[^3\text{H}]\text{Ins}(1,4,5)\text{P}_3$ were seen at 10 s, whereas at 5 min this had decreased to a value insignificantly different from basal values. Slower increases in $[^3\text{H}]\text{Ins}(1,3,4)\text{P}_3$ (229%) and $[^3\text{H}]\text{InsP}_4$ (165%) were also noted by analysis at 5 min. At this later time point, radioactivity eluting with characteristics of $\text{Ins}1\text{P}_1$ or $\text{Ins}3\text{P}_1$, $\text{Ins}4\text{P}_1$ and $\text{Ins}(1,4)\text{P}_2/\text{Ins}(1,3)\text{P}_2$ were all significantly increased by muscarinic receptor stimulation. Although the radioactivity eluting as InsP_4 was not definitively identified as $\text{Ins}(1,3,4,5)\text{P}_4$ [$\text{Ins}(1,3,4,6)\text{P}_4$ and $\text{Ins}(3,4,5,6)\text{P}_4$ also co-elute under these conditions], the identification of $[^3\text{H}]\text{Ins}(1,3,4)\text{P}_3$ and both $[^3\text{H}]\text{Ins}(1,4)\text{P}_2$ and $[^3\text{H}]\text{Ins}(1,3)\text{P}_2$ strongly suggests that metabolism of $\text{Ins}(1,4,5)\text{P}_3$ proceeds in stimulated cells via dephosphorylation or phosphorylation followed by dephosphorylation of $\text{Ins}(1,3,4,5)\text{P}_4$ [1].

The recent availability of methods to specifically assay the mass of $\text{Ins}(1,4,5)\text{P}_3$ and $\text{Ins}(1,3,4,5)\text{P}_4$ using radioreceptor techniques has been particularly useful here. The problems of changing specific radioactivity during agonist stimulation, and particularly the problem of separating isomeric species of InsP_3

Table 1. H.p.l.c. analysis of inositol phosphate isomers in carbachol (1 mM)-stimulated SH-SY5Y cells

Cells were prelabelled with 10 μ Ci of *myo*-[³H]inositol/ml for 48 h. Inositol phosphate isomers were separated by h.p.l.c. (see the text) Background radioactivity was subtracted from each fraction (InsP_{1/2} = 21, InsP₃ = 46, InsP₄ = 70 d.p.m.). Data are means \pm s.e.m., $n = 3-4$ (% increases are given in parentheses); * $P < 0.05$ compared with basal.

Inositol phosphate	Basal	Radioactivity (d.p.m.) (%)	
		10 s	5 min
Ins1P ₁	1125 \pm 75	1853 \pm 197 (64)*	2748 \pm 369 (144)*
Ins4P ₁	545 \pm 141	787 \pm 135 (44)	1798 \pm 307 (230)*
Ins(1,3)P ₂	83 \pm 23	125 \pm 40 (50)	273 \pm 79 (228)*
Ins(1,4)P ₂	1162 \pm 29	1584 \pm 143 (36)	1996 \pm 338 (71)*
Ins(1,3,4)P ₃	84 \pm 37	146 \pm 98 (73)	276 \pm 70 (229)*
Ins(1,4,5)P ₃	207 \pm 31	542 \pm 12 (162)*	334 \pm 74 (61)
InsP ₄	188 \pm 12	277 \pm 86 (47)	499 \pm 51 (165)*

and InsP₄, even with h.p.l.c., are overcome with assays that are stereo- and positionally specific. Indeed, they provide information on the potential errors of labelling experiments. When incubations were terminated at 10 s, carbachol induced a dose-related accumulation of Ins(1,4,5)P₃ mass. Maximum and half-maximum stimulation occurred at 1 mM and 42 \pm 18 μ M respectively (Fig. 1b). As reported previously [9], carbachol (1 mM) caused a biphasic increase in Ins(1,4,5)P₃ mass, reaching a maximal level some 10 s after agonist addition and then declining to a new steady state (above basal) by 1 min, and at 5 min was still significantly ($P < 0.05$) increased above basal. Omission of Ca²⁺ (+0.1 mM-EGTA) from the incubation buffer significantly reduced the plateau phase without affecting the peak Ins(1,4,5)P₃ mass. Analysis of peak-to-plateau ratios show that in control cells the plateau was 49 \pm 4 % of the peak value, whereas in cells devoid of extracellular Ca²⁺ this value was only 21 \pm 1 % ($P < 0.05$) (Fig. 1c).

Resting concentrations of Ins(1,3,4,5)P₄ in SH-SY5Y cells (approx. 6.1 \pm 1.2 pmol/mg of protein) are less than those of Ins(1,4,5)P₃ in these cells, but are very similar to those we have reported in cerebral cortical slices [14], and to those reported using a metal-dye technique in HL60 cells [17] and in NG108 cells using a similar receptor assay [18]. Stimulation by carbachol increased the mass of Ins(1,3,4,5)P₄ from 6.1 pmol/mg of protein to 47.0 pmol/mg of protein by 30 s, and this accumulation remained unchanged for a further 90 s before declining to 23.3 pmol/mg of protein at 5 min, a level still significantly above basal (see Fig. 1d). The increase observed at 60 s was dose-dependent, with maximum and half-maximum stimulation occurring at 1 mM and 31 \pm 4 μ M respectively (Fig. 1b). The EC₅₀ values for the mass of Ins(1,4,5)P₃ and the mass of Ins(1,3,4,5)P₄ did not differ significantly. In experiments in which extracellular Ca²⁺ was omitted (+0.1 mM-EGTA), the pattern of Ins(1,3,4,5)P₄ accumulation after carbachol was changed significantly. Under Ca²⁺-free conditions, although this polyphosphate accumulated initially, a significant reduction in Ins(1,3,4,5)P₄ was observed at 1 min, and by 5 min after agonist addition Ins(1,3,4,5)P₄ had returned to the basal level. Omission of Ca²⁺ did not alter the basal levels of this polyphosphate (Fig. 1d).

It should be noted that the mass measurements of Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ always gave much larger fold stimulations than comparable radioactive Dowex/h.p.l.c. peaks associated with labelled SH-SY5Y cells. Although these data would be consistent with a fall in specific radioactivity following receptor stimulation, we feel it is more likely that these discrepancies relate to other labelled (isomeric) species eluting in the [³H]InsP₃ and [³H]InsP₄ fractions and are proportionately more significant

in basal samples. These observations highlight the advantages of the mass assays.

The initial accumulation of Ins(1,4,5)P₃ {and perhaps of Ins(1,3,4,5)P₄ [19,20]} are almost certainly responsible for the release of Ca²⁺ from intracellular stores [7,21]. However, the significance of the sustained accumulation of Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ in SH-SY5Y cells is unclear. The time course of these responses parallels a phase of Ca²⁺ entry which has been carefully evaluated in previous studies in these cells [9]. This agonist-sensitive entry of Ca²⁺ is not mediated by voltage-sensitive Ca²⁺ channels [22], and we have discussed the possibility of a direct receptor-operated channel (although not involving a pertussis-toxin-sensitive G-protein [23]) or second-messenger-operated Ca²⁺ entry [24]. It should be further emphasized that Ca²⁺ entry in SH-SY5Y cells occurs at lower carbachol concentrations than are required for intracellular Ca²⁺ mobilization. Furthermore, the EC₅₀ value of carbachol stimulation of Ca²⁺ entry [9] is more than one order of magnitude lower than the EC₅₀ for its effects on Ins(1,4,5)P₃/Ins(1,3,4,5)P₄ accumulation. This latter point argues against inositol phosphates mediating Ca²⁺ entry.

Two recent studies in which [³H]Ins(1,3,4,5)P₄ has been separated from other inositol tetrakisphosphate isomers have reported a good temporal relationship between [³H]Ins(1,3,4,5)P₄ [but not Ins(1,4,5)P₃] accumulation and Ca²⁺ influx in bradykinin-stimulated PC12 cells [25] and HL60 cells activated with fMetLeuPhe [26]. Results in the present study using mass assays indicate a close correlation of both Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ with Ca²⁺ entry in SH-SY5Y cells. However, stimulating the cells with carbachol in the absence of extracellular Ca²⁺ markedly suppressed the later sustained accumulation of inositol polyphosphates. These data may be consistent with a model in which the later accumulation of Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ is dependent upon Ca²⁺ entry rather than vice versa. However, since we know that Ca²⁺ entry is a very early event (probably occurring in concert with the discharge of the internal stores) in these cells [9], it still remains possible that Ins(1,4,5)P₃ and/or Ins(1,3,4,5)P₄ may open the Ca²⁺ channel and that the subsequent Ca²⁺-dependent sustained accumulation of these second messengers may maintain the Ca²⁺ channel in the open state in a positive feedback system.

Thus, in conclusion, we have established using both labelling and mass assays the generation and accumulation of the second messengers Ins(1,4,5)P₃ and Ins(1,3,4,5)P₄ after muscarinic M₃ receptor stimulation in SH-SY5Y cells. The later sustained accumulation of these inositol polyphosphates appears to be dependent upon extracellular Ca²⁺. A Ca²⁺-stimulated hydrolysis

of phosphoinositides has been observed in these cells [16], and in detailed studies on the parent SK-N-SH cell, Fisher *et al.* [8] have demonstrated synergism for inositol phosphate generation between Ca^{2+} in the micromolar range and guanine nucleotides. Our data appear consistent with a direct receptor-operated Ca^{2+} entry that is separate from intracellular release, as recently established in bovine adrenal chromaffin cells [27].

We thank the Wellcome Trust for financial support and NEN (DuPont) for generously providing [^3H]Ins(1,4,5) P_3 , [^3H]Ins(1,3,4,5) P_4 and [^{32}P]Ins(1,3,4,5) P_4 .

REFERENCES

1. Shears, S. B. (1990) *Biochem. J.* **260**, 313–324
2. Berridge, M. J. & Irvine, R. F. (1989) *Nature (London)* **341**, 197–204
3. Nahorski, S. R. (1988) *Trends Neurosci.* **10**, 444–448
4. Irvine, R. F. (1990) *FEBS Lett.* **263**, 5–9
5. Lambert, D. G., Ghataorje, S. R. & Nahorski, S. R. (1989) *Eur. J. Pharmacol.* **165**, 71–77
6. Fisher, S. K. & Heacock, A. M. (1988) *J. Neurochem.* **50**, 984–987
7. Baird, J. G., Lambert, D. G., McBain, J. & Nahorski, S. R. (1989) *Br. J. Pharmacol.* **98**, 1328–1334
8. Fisher, S. K., Domask, L. M. & Roland, R. M. (1989) *Mol. Pharmacol.* **35**, 195–204
9. Lambert, D. G. & Nahorski, S. R. (1990) *Biochem. J.* **265**, 555–562
10. Berridge, M. J., Dawson, R. M. C., Downes, C. P., Heslop, J. P. & Irvine, R. F. (1983) *Biochem. J.* **212**, 473–482
11. Batty, I. H., Nahorski, S. R. & Irvine, S. R. (1985) *Biochem. J.* **232**, 211–215
12. Batty, I. H., Letcher, A. J. & Nahorski, S. R. (1989) *Biochem. J.* **258**, 23–32
13. Challiss, R. A. J., Batty, I. H. & Nahorski, S. R. (1988) *Biochem. Biophys. Res. Commun.* **157**, 684–691
14. Challiss, R. A. J. & Nahorski, S. R. (1990) *J. Neurochem.* **54**, 2138–2141
15. De Lean, A., Munson, P. J. & Rodbard, D. (1978) *Am. J. Physiol.* **235**, E97–E102
16. Wojcikiewicz, R. J. H., Lambert, D. G. & Nahorski, S. R. (1990) *J. Neurochem.* **54**, 676–685
17. Pittet, D., Schlegel, W., Monod, A. & Mayr, G. W. (1989) *J. Biol. Chem.* **264**, 18489–18493
18. Donie, F. & Riser, G. (1989) *FEBS Lett.* **254**, 155–158
19. Joseph, S. K., Hansen, C. A. & Williamson, J. R. (1989) *Mol. Pharmacol.* **36**, 391–397
20. Gawler, D. J., Potter, B. V. L. & Nahorski, S. R. (1990) *Biochem. J.* **272**, 519–524
21. Wojcikiewicz, R. J. H., Safranay, S. T., Challiss, R. A. J., Strupish, J. & Nahorski, S. R. (1990) *Biochem. J.* **272**, 269–272
22. Lambert, D. G., Whitham, E. M., Baird, J. G. & Nahorski, S. R. (1990) *Mol. Brain Res.* **8**, 263–266
23. Lambert, D. G. & Nahorski, S. R. (1990) *Biochem. Pharmacol.* **40**, 2291–2295
24. Lambert, D. G. & Nahorski, S. R. (1990) in *Progress in Brain Research* (Aquilonius, S.-M. & Gillberg, P.-G., eds.), pp. 31–42, Elsevier, Amsterdam
25. Fasolato, C., Pandiella, A., Meldolesi, J. & Pozzan, T. (1988) *J. Biol. Chem.* **263**, 17350–17359
26. Pittet, D., Lew, D. P., Mayr, G. W., Monod, A. & Schlegel, W. (1989) *J. Biol. Chem.* **264**, 7251–7261
27. Stauderman, K. A. & Pruss, R. M. (1989) *J. Biol. Chem.* **264**, 18349–18355

Received 3 September 1990/14 November 1990; accepted 26 November 1990